Genfit prices IPO at $135m
French liver disorder specialist Genfit SA has announced the pricing of its Nasdaq IPO of ADS and European private placement.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1162 entries already.
Entries by Thomas Gabrielczyk
Evotec partners with Mark Foundation for Cancer Research
/in News/by Thomas GabrielczykEvotec AG and The Mark Foundation for Cancer Research have inked a R&D collaboration aimed at developing novel immunooncological drugs
BIO-Europe Spring: Partnering deluxe
/in News/by Thomas GabrielczykThe 13th annual BIO-Europe Spring international partnering conference will be held in Vienna, Austria, for the first time, March 2527, 2019, at the Messe Wien Exhibition and Congress Center. The […]
New approach to treat eye cancer
/in News/by Thomas GabrielczykA research team from Germany and Mexico has successfully targeted uveal melanoma (UM), the most common type of eye cancer.
Pfizer buys stake in liver gene therapy player Vivet
/in News/by Thomas GabrielczykPfizer Inc has paid 45m upfront to French gene therapy specalist Vivet Therapeutics in a licence option deal for Vivet’s preclinical Wilson disease candidate VTX-801.
Sotio on track for 2nd Phase III trial
/in News/by Thomas GabrielczykAfter positive preliminary results of Sotio’s SOV02 trial in ovarian cancer had been presented last year, the final analysis confirmed the survival benefits. The Czech biotech company now plans to […]
AMR Conference in Berlin: Call for better incentives
/in News/by Thomas GabrielczykMore than 330 experts joined the 2-day AMR Conference 2019 in Berlin. They called for rapid capital investments and economic incentives in the fight against antimicrobial resistance (AMR).
Biomarker can exclude acute kidney injury
/in News/by Thomas GabrielczykData presented at the 24th AKI & CRRT conference, suggest that the kidney function marker pro-enkephalin (penKid) is capable to rule out acute kidney injury (AKI) with a single measurement.
Researchers target neuroblastoma with ALK-ADC
/in News/by Thomas GabrielczykResearchers at Celldex Therapeutics, Inc and Nerviano Medical Science Srl report elimination of the most common childhood cancer by an ADC in xenografted mice expressing either wild-type or mutated ALK.
AMR: Germany set to invest 39m into CARB-X
/in News/by Thomas GabrielczykGlobal antibacterial innovation network CARB-X announced during an AMR business conference in Berlin that Germany has joined the CARB-X partnership.